Salix risk/reward favorable ahead of trial, says Stifel Stifel is comfortable owning Salix ahead of the expected release of TARGET-3 retreatment data for Xifaxan in diarrhea-related IBS in coming weeks. The firm thinks the stock could rise significantly if the data is positive, while a decline in shares on negative results would create a buying opportunity. The firm thinks there is a 65%-70% chance that the data will be positive, and it estimates that the stock could climb up to 20%-25% on positive data. It keeps a Buy rating on the stock.
Salix upgraded to Buy from Neutral at UBS UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.